MarketBeat Reports Consensus Rating and Earnings Estimates for Coherus Oncology
1 report, 1 independent
Updated Tue 00:00
AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat reported the consensus rating for Coherus Oncology, Inc. based on analyst research notes. HC Wainwright issued Q3 2026 earnings per share estimates, expecting the company to earn $0.22 per share for the quarter and maintaining a “Buy” rating. Separately, Weiss Ratings upgraded shares of Coherus Oncology from a “sell (e+)” rating to a “sell (d-)” rating.
From themarketsdaily.com
Why it matters
The reports provide detailed earnings forecasts through 2030, with the current consensus estimate for full-year 2026 earnings standing at ($0.88) per share. MarketBeat currently reflects a consensus rating of “Moderate Buy” for the company.
From themarketsdaily.com
Who's involved
- MarketBeatAggregated and reported the consensus rating and analyst estimates
Keep exploring
The entities involved
-
MarketBeat
American personal finance blog
Related events
- MarketBeat reported the consensus rating for Diaceutics PLC.
- MarketBeat provided consensus rating data for TuHURA Biosciences, Inc. on November 1, 2026.
- MarketBeat provided consensus rating data for Zhengye Biotechnology Holding Limited on October 31, 2026.
- MarketBeat reported the consensus rating for Energous Corporation on October 18, 2026.
- MarketBeat provided average rating data for the stock, and Citigroup began coverage on Whitehawk Therapeutics shares.